메뉴 건너뛰기




Volumn 88, Issue 3, 2013, Pages 655-666

Targeting inflammatory pathways in chronic lymphocytic leukemia

Author keywords

Chronic lymphocytic leukemia; CLL; Experimental therapy; Inflammation

Indexed keywords

B LYMPHOCYTE RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DASATINIB; FOSTAMATINIB; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

EID: 84888301257     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.011     Document Type: Review
Times cited : (29)

References (106)
  • 1
    • 33847093215 scopus 로고    scopus 로고
    • Staging and prognosis of chronic lymphcoytie leukemia
    • UpToDate, Waltham, MA, B.D. Rose (Ed.)
    • Rai K.R., Keating M.J. Staging and prognosis of chronic lymphcoytie leukemia. UpToDate 2013, UpToDate, Waltham, MA. B.D. Rose (Ed.).
    • (2013) UpToDate
    • Rai, K.R.1    Keating, M.J.2
  • 2
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3    Caligaris-Cappio, F.4    Dighiero, G.5    Dohner, H.6
  • 3
    • 0023589395 scopus 로고
    • Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases
    • Duhrsen U., Augener W., Zwingers T., Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. British Journal of Haematology 1987, 67:235-239.
    • (1987) British Journal of Haematology , vol.67 , pp. 235-239
    • Duhrsen, U.1    Augener, W.2    Zwingers, T.3    Brittinger, G.4
  • 4
    • 0001441734 scopus 로고
    • Exaggerated Delayed Hypersensitivity to Mosquito Bites in Chronic Lymphocytic Leukemia
    • Weed R.I. Exaggerated Delayed Hypersensitivity to Mosquito Bites in Chronic Lymphocytic Leukemia. Blood 1965, 26:257-268.
    • (1965) Blood , vol.26 , pp. 257-268
    • Weed, R.I.1
  • 5
    • 0031851981 scopus 로고    scopus 로고
    • Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients
    • Davis M.D., Perniciaro C., Dahl P.R., Randle H.W., McEvoy M.T., Leiferman K.M. Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients. Journal of the American Academy of Dermatology 1998, 39:27-35.
    • (1998) Journal of the American Academy of Dermatology , vol.39 , pp. 27-35
    • Davis, M.D.1    Perniciaro, C.2    Dahl, P.R.3    Randle, H.W.4    McEvoy, M.T.5    Leiferman, K.M.6
  • 9
    • 63749084353 scopus 로고    scopus 로고
    • Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment
    • Wierda W.G., O'Brien S., Wang X., Faderl S., Ferrajoli A., Do K.A., et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. Journal of Clinical Oncology 2009, 27:1637-1643.
    • (2009) Journal of Clinical Oncology , vol.27 , pp. 1637-1643
    • Wierda, W.G.1    O'Brien, S.2    Wang, X.3    Faderl, S.4    Ferrajoli, A.5    Do, K.A.6
  • 10
    • 0038062843 scopus 로고    scopus 로고
    • Beta2-microglobulin as a potential initiator of inflammatory responses
    • author reply 9-30
    • Xie J., Yi Q. Beta2-microglobulin as a potential initiator of inflammatory responses. Trends in Immunology 2003, 24:228-229. author reply 9-30.
    • (2003) Trends in Immunology , vol.24 , pp. 228-229
    • Xie, J.1    Yi, Q.2
  • 11
    • 81155133323 scopus 로고    scopus 로고
    • Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia
    • Yan X.J., Dozmorov I., Li W., Yancopoulos S., Sison C., Centola M., et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 2011, 118:5201-5210.
    • (2011) Blood , vol.118 , pp. 5201-5210
    • Yan, X.J.1    Dozmorov, I.2    Li, W.3    Yancopoulos, S.4    Sison, C.5    Centola, M.6
  • 12
    • 81155150157 scopus 로고    scopus 로고
    • Gene expression and serum cytokine profiling of low stage CLL identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as regulators of cell proliferation, survival and migration
    • Mahadevan D., Choi J., Cooke L., Simons B., Riley C., Klinkhammer T., et al. Gene expression and serum cytokine profiling of low stage CLL identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as regulators of cell proliferation, survival and migration. Human Genomics and Proteomics 2009, 2009:453634.
    • (2009) Human Genomics and Proteomics , vol.2009 , pp. 453634
    • Mahadevan, D.1    Choi, J.2    Cooke, L.3    Simons, B.4    Riley, C.5    Klinkhammer, T.6
  • 13
    • 0035160749 scopus 로고    scopus 로고
    • Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
    • Fayad L., Keating M.J., Reuben J.M., O'Brien S., Lee B.N., Lerner S., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001, 97:256-263.
    • (2001) Blood , vol.97 , pp. 256-263
    • Fayad, L.1    Keating, M.J.2    Reuben, J.M.3    O'Brien, S.4    Lee, B.N.5    Lerner, S.6
  • 14
    • 84864995278 scopus 로고    scopus 로고
    • Association of interleukin-6 and interleukin-8 with poor prognosis in elderly chronic lymphocytic leukemia patients
    • Yoon J.Y., Lafarge S., Dawe D., Lakhi S., Kumar R., Morales C., et al. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly chronic lymphocytic leukemia patients. Leukemia and Lymphoma 2012.
    • (2012) Leukemia and Lymphoma
    • Yoon, J.Y.1    Lafarge, S.2    Dawe, D.3    Lakhi, S.4    Kumar, R.5    Morales, C.6
  • 16
    • 80955133848 scopus 로고    scopus 로고
    • Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3
    • Badoux X., Bueso-Ramos C., Harris D., Li P., Liu Z., Burger J., et al. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Human Pathology 2011, 42:1989-2000.
    • (2011) Human Pathology , vol.42 , pp. 1989-2000
    • Badoux, X.1    Bueso-Ramos, C.2    Harris, D.3    Li, P.4    Liu, Z.5    Burger, J.6
  • 17
  • 18
    • 84855987240 scopus 로고    scopus 로고
    • Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells
    • Dietrich S., Kramer O.H., Hahn E., Schafer C., Giese T., Hess M., et al. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clinical Cancer Research 2012, 18:417-431.
    • (2012) Clinical Cancer Research , vol.18 , pp. 417-431
    • Dietrich, S.1    Kramer, O.H.2    Hahn, E.3    Schafer, C.4    Giese, T.5    Hess, M.6
  • 19
    • 0030986972 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta
    • Douglas R.S., Capocasale R.J., Lamb R.J., Nowell P.C., Moore J.S. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 1997, 89:941-947.
    • (1997) Blood , vol.89 , pp. 941-947
    • Douglas, R.S.1    Capocasale, R.J.2    Lamb, R.J.3    Nowell, P.C.4    Moore, J.S.5
  • 20
    • 9144220762 scopus 로고    scopus 로고
    • Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway
    • Kern C., Cornuel J.F., Billard C., Tang R., Rouillard D., Stenou V., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004, 103:679-688.
    • (2004) Blood , vol.103 , pp. 679-688
    • Kern, C.1    Cornuel, J.F.2    Billard, C.3    Tang, R.4    Rouillard, D.5    Stenou, V.6
  • 21
    • 69949086416 scopus 로고    scopus 로고
    • Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases
    • Del Giudice I., Chiaretti S., Tavolaro S., De Propris M.S., Maggio R., Mancini F., et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 2009, 114:638-646.
    • (2009) Blood , vol.114 , pp. 638-646
    • Del Giudice, I.1    Chiaretti, S.2    Tavolaro, S.3    De Propris, M.S.4    Maggio, R.5    Mancini, F.6
  • 22
    • 43449101911 scopus 로고    scopus 로고
    • Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia
    • Palmer S., Hanson C.A., Zent C.S., Porrata L.F., Laplant B., Geyer S.M., et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. British Journal of Haematology 2008, 141:607-614.
    • (2008) British Journal of Haematology , vol.141 , pp. 607-614
    • Palmer, S.1    Hanson, C.A.2    Zent, C.S.3    Porrata, L.F.4    Laplant, B.5    Geyer, S.M.6
  • 24
    • 84856515333 scopus 로고    scopus 로고
    • Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression
    • Nunes C., Wong R., Mason M., Fegan C., Man S., Pepper C. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 2012, 18:678-687.
    • (2012) Clinical Cancer Research , vol.18 , pp. 678-687
    • Nunes, C.1    Wong, R.2    Mason, M.3    Fegan, C.4    Man, S.5    Pepper, C.6
  • 25
    • 0032101593 scopus 로고    scopus 로고
    • Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia
    • Tinhofer I., Marschitz I., Kos M., Henn T., Egle A., Villunger A., et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998, 91:4273-4281.
    • (1998) Blood , vol.91 , pp. 4273-4281
    • Tinhofer, I.1    Marschitz, I.2    Kos, M.3    Henn, T.4    Egle, A.5    Villunger, A.6
  • 26
    • 0030846220 scopus 로고    scopus 로고
    • Acquired CD40-ligand deficiency in chronic lymphocytic leukemia
    • Cantwell M., Hua T., Pappas J., Kipps T.J. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Medicine 1997, 3:984-989.
    • (1997) Nature Medicine , vol.3 , pp. 984-989
    • Cantwell, M.1    Hua, T.2    Pappas, J.3    Kipps, T.J.4
  • 27
    • 0029942655 scopus 로고    scopus 로고
    • Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia
    • Rossi E., Matutes E., Morilla R., Owusu-Ankomah K., Heffernan A.M., Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996, 10:494-497.
    • (1996) Leukemia , vol.10 , pp. 494-497
    • Rossi, E.1    Matutes, E.2    Morilla, R.3    Owusu-Ankomah, K.4    Heffernan, A.M.5    Catovsky, D.6
  • 28
    • 0034667624 scopus 로고    scopus 로고
    • Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
    • Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
    • (2000) Blood , vol.96 , pp. 2655-2663
    • Burger, J.A.1    Tsukada, N.2    Burger, M.3    Zvaifler, N.J.4    Dell'Aquila, M.5    Kipps, T.J.6
  • 29
    • 64049093376 scopus 로고    scopus 로고
    • High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
    • Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
    • (2009) Blood , vol.113 , pp. 3050-3058
    • Burger, J.A.1    Quiroga, M.P.2    Hartmann, E.3    Burkle, A.4    Wierda, W.G.5    Keating, M.J.6
  • 31
    • 0036884819 scopus 로고    scopus 로고
    • Regulation of B-cell fate by antigen-receptor signals
    • Niiro H., Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nature Reviews Immunology 2002, 2:945-956.
    • (2002) Nature Reviews Immunology , vol.2 , pp. 945-956
    • Niiro, H.1    Clark, E.A.2
  • 32
    • 78049287668 scopus 로고    scopus 로고
    • The tipping points in the initiation of B cell signalling: how small changes make big differences
    • Pierce S.K., Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nature Reviews Immunology 2010, 10:767-777.
    • (2010) Nature Reviews Immunology , vol.10 , pp. 767-777
    • Pierce, S.K.1    Liu, W.2
  • 33
    • 0037204949 scopus 로고    scopus 로고
    • B cell antigen receptor signaling: roles in cell development and disease
    • Gauld S.B., Dal Porto J.M., Cambier J.C. B cell antigen receptor signaling: roles in cell development and disease. Science 2002, 296:1641-1642.
    • (2002) Science , vol.296 , pp. 1641-1642
    • Gauld, S.B.1    Dal Porto, J.M.2    Cambier, J.C.3
  • 34
    • 0042971643 scopus 로고    scopus 로고
    • B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor
    • Chiorazzi N., Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annual Review of Immunology 2003, 21:841-894.
    • (2003) Annual Review of Immunology , vol.21 , pp. 841-894
    • Chiorazzi, N.1    Ferrarini, M.2
  • 35
    • 2942584865 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia: revelations from the B-cell receptor
    • Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103:4389-4395.
    • (2004) Blood , vol.103 , pp. 4389-4395
    • Stevenson, F.K.1    Caligaris-Cappio, F.2
  • 37
    • 33846108722 scopus 로고    scopus 로고
    • Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations
    • Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
    • (2007) Blood , vol.109 , pp. 259-270
    • Stamatopoulos, K.1    Belessi, C.2    Moreno, C.3    Boudjograh, M.4    Guida, G.5    Smilevska, T.6
  • 38
    • 4944244255 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins
    • Widhopf G.F., Rassenti L.Z., Toy T.L., Gribben J.G., Wierda W.G., Kipps T.J. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004, 104:2499-2504.
    • (2004) Blood , vol.104 , pp. 2499-2504
    • Widhopf, G.F.1    Rassenti, L.Z.2    Toy, T.L.3    Gribben, J.G.4    Wierda, W.G.5    Kipps, T.J.6
  • 40
    • 56349091862 scopus 로고    scopus 로고
    • Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling
    • Stadanlick J.E., Kaileh M., Karnell F.G., Scholz J.L., Miller J.P., Quinn W.J., et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nature Immunology 2008, 9:1379-1387.
    • (2008) Nature Immunology , vol.9 , pp. 1379-1387
    • Stadanlick, J.E.1    Kaileh, M.2    Karnell, F.G.3    Scholz, J.L.4    Miller, J.P.5    Quinn, W.J.6
  • 41
    • 0031436969 scopus 로고    scopus 로고
    • B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues
    • Frank D.A., Mahajan S., Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. Journal of Clinical Investigation 1997, 100:3140-3148.
    • (1997) Journal of Clinical Investigation , vol.100 , pp. 3140-3148
    • Frank, D.A.1    Mahajan, S.2    Ritz, J.3
  • 43
    • 84555171449 scopus 로고    scopus 로고
    • Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
    • Quesada V., Conde L., Villamor N., Ordonez G.R., Jares P., Bassaganyas L., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics 2012, 44:47-52.
    • (2012) Nature Genetics , vol.44 , pp. 47-52
    • Quesada, V.1    Conde, L.2    Villamor, N.3    Ordonez, G.R.4    Jares, P.5    Bassaganyas, L.6
  • 45
    • 79960036578 scopus 로고    scopus 로고
    • Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
    • Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
    • (2011) Nature , vol.475 , pp. 101-105
    • Puente, X.S.1    Pinyol, M.2    Quesada, V.3    Conde, L.4    Ordonez, G.R.5    Villamor, N.6
  • 46
    • 33749490571 scopus 로고    scopus 로고
    • Innate immune recognition of, and regulation by, DNA
    • Ishii K.J., Akira S. Innate immune recognition of, and regulation by, DNA. Trends in Immunology 2006, 27:525-532.
    • (2006) Trends in Immunology , vol.27 , pp. 525-532
    • Ishii, K.J.1    Akira, S.2
  • 47
    • 74549167783 scopus 로고    scopus 로고
    • Regulation of adaptive immunity by the innate immune system
    • Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
    • (2010) Science , vol.327 , pp. 291-295
    • Iwasaki, A.1    Medzhitov, R.2
  • 50
    • 0035093737 scopus 로고    scopus 로고
    • DNA double-strand breaks: signaling, repair and the cancer connection
    • Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genetics 2001, 27:247-254.
    • (2001) Nature Genetics , vol.27 , pp. 247-254
    • Khanna, K.K.1    Jackson, S.P.2
  • 52
    • 0029614780 scopus 로고
    • Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease
    • Fegan C., Robinson H., Thompson P., Whittaker J.A., White D. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995, 9:2003-2008.
    • (1995) Leukemia , vol.9 , pp. 2003-2008
    • Fegan, C.1    Robinson, H.2    Thompson, P.3    Whittaker, J.A.4    White, D.5
  • 53
    • 36849045647 scopus 로고    scopus 로고
    • Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion
    • Austen B., Skowronska A., Baker C., Powell J.E., Gardiner A., Oscier D., et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. Journal of Clinical Oncology 2007, 25:5448-5457.
    • (2007) Journal of Clinical Oncology , vol.25 , pp. 5448-5457
    • Austen, B.1    Skowronska, A.2    Baker, C.3    Powell, J.E.4    Gardiner, A.5    Oscier, D.6
  • 54
    • 84855231198 scopus 로고    scopus 로고
    • ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression
    • Guarini A., Marinelli M., Tavolaro S., Bellacchio E., Magliozzi M., Chiaretti S., et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012, 97:47-55.
    • (2012) Haematologica , vol.97 , pp. 47-55
    • Guarini, A.1    Marinelli, M.2    Tavolaro, S.3    Bellacchio, E.4    Magliozzi, M.5    Chiaretti, S.6
  • 55
    • 0014494703 scopus 로고
    • Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia
    • Ezdinli E.Z., Stutzman L., Aungst C.W., Firat D. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 1969, 23:900-909.
    • (1969) Cancer , vol.23 , pp. 900-909
    • Ezdinli, E.Z.1    Stutzman, L.2    Aungst, C.W.3    Firat, D.4
  • 56
    • 0036278515 scopus 로고    scopus 로고
    • Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies
    • Greenstein S., Ghias K., Krett N.L., Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clinical Cancer Research 2002, 8:1681-1694.
    • (2002) Clinical Cancer Research , vol.8 , pp. 1681-1694
    • Greenstein, S.1    Ghias, K.2    Krett, N.L.3    Rosen, S.T.4
  • 57
    • 0027985130 scopus 로고
    • High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients
    • Molica S. High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients. American Journal of Hematology 1994, 47:334.
    • (1994) American Journal of Hematology , vol.47 , pp. 334
    • Molica, S.1
  • 59
    • 0032529499 scopus 로고    scopus 로고
    • Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells
    • Bellosillo B., Pique M., Barragan M., Castano E., Villamor N., Colomer D., et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood. 1998, 92:1406-1414.
    • (1998) Blood. , vol.92 , pp. 1406-1414
    • Bellosillo, B.1    Pique, M.2    Barragan, M.3    Castano, E.4    Villamor, N.5    Colomer, D.6
  • 60
    • 33745181682 scopus 로고    scopus 로고
    • Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells
    • Ryan E.P., Pollock S.J., Kaur K., Felgar R.E., Bernstein S.H., Chiorazzi N., et al. Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clinical Immunology 2006, 120:76-90.
    • (2006) Clinical Immunology , vol.120 , pp. 76-90
    • Ryan, E.P.1    Pollock, S.J.2    Kaur, K.3    Felgar, R.E.4    Bernstein, S.H.5    Chiorazzi, N.6
  • 61
    • 37349131556 scopus 로고    scopus 로고
    • Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells
    • Ryan E.P., Bushnell T.P., Friedman A.E., Rahman I., Phipps R.P. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunology, Immunotherapy 2008, 57:347-358.
    • (2008) Cancer Immunology, Immunotherapy , vol.57 , pp. 347-358
    • Ryan, E.P.1    Bushnell, T.P.2    Friedman, A.E.3    Rahman, I.4    Phipps, R.P.5
  • 62
    • 77954097693 scopus 로고    scopus 로고
    • Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia
    • Shanafelt T.D., Rabe K.G., Kay N.E., Zent C.S., Call T.G., Slager S.L., et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leukemia and Lymphoma 2010, 51:1233-1240.
    • (2010) Leukemia and Lymphoma , vol.51 , pp. 1233-1240
    • Shanafelt, T.D.1    Rabe, K.G.2    Kay, N.E.3    Zent, C.S.4    Call, T.G.5    Slager, S.L.6
  • 63
    • 33845584467 scopus 로고    scopus 로고
    • Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells
    • Robak P., Linke A., Cebula B., Robak T., Smolewski P. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leukemia and Lymphoma 2006, 47:2625-2634.
    • (2006) Leukemia and Lymphoma , vol.47 , pp. 2625-2634
    • Robak, P.1    Linke, A.2    Cebula, B.3    Robak, T.4    Smolewski, P.5
  • 64
    • 34447513090 scopus 로고    scopus 로고
    • R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells
    • Lindhagen E., Nissle S., Leoni L., Elliott G., Chao Q., Larsson R., et al. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemotherapy and Pharmacology 2007, 60:545-553.
    • (2007) Cancer Chemotherapy and Pharmacology , vol.60 , pp. 545-553
    • Lindhagen, E.1    Nissle, S.2    Leoni, L.3    Elliott, G.4    Chao, Q.5    Larsson, R.6
  • 69
    • 2942720515 scopus 로고    scopus 로고
    • Beneficial cardiovascular pleiotropic effects of statins
    • Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III39-III43.
    • (2004) Circulation , vol.109 , pp. 339-343
    • Davignon, J.1
  • 70
    • 0346736491 scopus 로고    scopus 로고
    • Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
    • Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation 1998, 101:2711-2719.
    • (1998) Journal of Clinical Investigation , vol.101 , pp. 2711-2719
    • Hernandez-Perera, O.1    Perez-Sala, D.2    Navarro-Antolin, J.3    Sanchez-Pascuala, R.4    Hernandez, G.5    Diaz, C.6
  • 72
    • 49949088655 scopus 로고    scopus 로고
    • Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability
    • Zhou M.S., Schuman I.H., Jaimes E.A., Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Renal Physiology. American Journal of Physiology 2008, 295:F53-F59.
    • (2008) Renal Physiology. American Journal of Physiology , vol.295
    • Zhou, M.S.1    Schuman, I.H.2    Jaimes, E.A.3    Raij, L.4
  • 75
    • 58149218510 scopus 로고    scopus 로고
    • Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation
    • Ulivieri C., Fanigliulo D., Benati D., Pasini F.L., Baldari C.T. Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation. European Journal of Immunology 2008, 38:2832-2844.
    • (2008) European Journal of Immunology , vol.38 , pp. 2832-2844
    • Ulivieri, C.1    Fanigliulo, D.2    Benati, D.3    Pasini, F.L.4    Baldari, C.T.5
  • 78
    • 84870734255 scopus 로고    scopus 로고
    • Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
    • Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120:4684-4691.
    • (2012) Blood , vol.120 , pp. 4684-4691
    • Wiestner, A.1
  • 81
    • 84861519200 scopus 로고    scopus 로고
    • Dasatinib inhibits proinflammatory functions of mature human neutrophils
    • Futosi K., Nemeth T., Pick R., Vantus T., Walzog B., Mocsai A. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012, 119:4981-4991.
    • (2012) Blood , vol.119 , pp. 4981-4991
    • Futosi, K.1    Nemeth, T.2    Pick, R.3    Vantus, T.4    Walzog, B.5    Mocsai, A.6
  • 83
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
    • (2010) Blood , vol.115 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3    Johnston, P.B.4    Vose, J.M.5    Lacasce, A.6
  • 84
    • 84865082196 scopus 로고    scopus 로고
    • Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia
    • Cheson B.D., Byrd J.C., Rai K.R., Kay N.E., O'Brien S.M., Flinn I.W., et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. Journal of Clinical Oncology 2012, 30:2820-2822.
    • (2012) Journal of Clinical Oncology , vol.30 , pp. 2820-2822
    • Cheson, B.D.1    Byrd, J.C.2    Rai, K.R.3    Kay, N.E.4    O'Brien, S.M.5    Flinn, I.W.6
  • 85
    • 84864436773 scopus 로고    scopus 로고
    • Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia
    • Herman S.E., Johnson A.J. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clinical Cancer Research 2012, 18:4013-4018.
    • (2012) Clinical Cancer Research , vol.18 , pp. 4013-4018
    • Herman, S.E.1    Johnson, A.J.2
  • 87
    • 79959404661 scopus 로고    scopus 로고
    • Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
    • Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
    • (2011) Blood , vol.117 , pp. 6287-6296
    • Herman, S.E.1    Gordon, A.L.2    Hertlein, E.3    Ramanunni, A.4    Zhang, X.5    Jaglowski, S.6
  • 89
    • 84863011553 scopus 로고    scopus 로고
    • The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
    • Ponader S., Chen S.S., Buggy J.J., Balakrishnan K., Gandhi V., Wierda W.G., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
    • (2012) Blood , vol.119 , pp. 1182-1189
    • Ponader, S.1    Chen, S.S.2    Buggy, J.J.3    Balakrishnan, K.4    Gandhi, V.5    Wierda, W.G.6
  • 90
    • 43749117945 scopus 로고    scopus 로고
    • Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
    • Rajkumar S.V., Rosinol L., Hussein M., Catalano J., Jedrzejczak W., Lucy L., et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology 2008, 26:2171-2177.
    • (2008) Journal of Clinical Oncology , vol.26 , pp. 2171-2177
    • Rajkumar, S.V.1    Rosinol, L.2    Hussein, M.3    Catalano, J.4    Jedrzejczak, W.5    Lucy, L.6
  • 92
    • 83255170962 scopus 로고    scopus 로고
    • Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia
    • Carballido E., Veliz M., Komrokji R., Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012, 19:54-67.
    • (2012) Cancer Control , vol.19 , pp. 54-67
    • Carballido, E.1    Veliz, M.2    Komrokji, R.3    Pinilla-Ibarz, J.4
  • 93
    • 0026080801 scopus 로고
    • Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
    • Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 1991, 173:699-703.
    • (1991) Journal of Experimental Medicine , vol.173 , pp. 699-703
    • Sampaio, E.P.1    Sarno, E.N.2    Galilly, R.3    Cohn, Z.A.4    Kaplan, G.5
  • 94
    • 84883833410 scopus 로고
    • Thalidomide in the treatment of lepra reactions
    • Sheskin J. Thalidomide in the treatment of lepra reactions. Clinical Pharmacology and Therapeutics 1965, 6:303-306.
    • (1965) Clinical Pharmacology and Therapeutics , vol.6 , pp. 303-306
    • Sheskin, J.1
  • 95
    • 0033168605 scopus 로고    scopus 로고
    • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
    • Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 1999, 163:380-386.
    • (1999) Journal of Immunology , vol.163 , pp. 380-386
    • Corral, L.G.1    Haslett, P.A.2    Muller, G.W.3    Chen, R.4    Wong, L.M.5    Ocampo, C.J.6
  • 96
    • 46749132717 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
    • Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation 2008, 118:2427-2437.
    • (2008) Journal of Clinical Investigation , vol.118 , pp. 2427-2437
    • Ramsay, A.G.1    Johnson, A.J.2    Lee, A.M.3    Gorgun, G.4    Le Dieu, R.5    Blum, W.6
  • 97
    • 80053350801 scopus 로고    scopus 로고
    • Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
    • Badoux X.C., Keating M.J., Wen S., Lee B.N., Sivina M., Reuben J., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
    • (2011) Blood , vol.118 , pp. 3489-3498
    • Badoux, X.C.1    Keating, M.J.2    Wen, S.3    Lee, B.N.4    Sivina, M.5    Reuben, J.6
  • 98
    • 33947243663 scopus 로고    scopus 로고
    • Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
    • Chanan-Khan A., Miller K.C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology 2006, 24:5343-5349.
    • (2006) Journal of Clinical Oncology , vol.24 , pp. 5343-5349
    • Chanan-Khan, A.1    Miller, K.C.2    Musial, L.3    Lawrence, D.4    Padmanabhan, S.5    Takeshita, K.6
  • 99
    • 79952769640 scopus 로고    scopus 로고
    • Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia
    • Chen C.I., Bergsagel P.L., Paul H., Xu W., Lau A., Dave N., et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. Journal of Clinical Oncology 2011, 29:1175-1181.
    • (2011) Journal of Clinical Oncology , vol.29 , pp. 1175-1181
    • Chen, C.I.1    Bergsagel, P.L.2    Paul, H.3    Xu, W.4    Lau, A.5    Dave, N.6
  • 100
    • 45949100928 scopus 로고    scopus 로고
    • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
    • Ferrajoli A., Lee B.N., Schlette E.J., O'Brien S.M., Gao H., Wen S., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
    • (2008) Blood , vol.111 , pp. 5291-5297
    • Ferrajoli, A.1    Lee, B.N.2    Schlette, E.J.3    O'Brien, S.M.4    Gao, H.5    Wen, S.6
  • 101
    • 41149168649 scopus 로고    scopus 로고
    • Lenalidomide for the treatment of B-cell malignancies
    • Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology 2008, 26:1544-1552.
    • (2008) Journal of Clinical Oncology , vol.26 , pp. 1544-1552
    • Chanan-Khan, A.A.1    Cheson, B.D.2
  • 102
    • 84867647498 scopus 로고    scopus 로고
    • Inflammation in aging: cause, effect, or both?
    • Jenny N.S. Inflammation in aging: cause, effect, or both?. Discovery Medicine 2012, 13:451-460.
    • (2012) Discovery Medicine , vol.13 , pp. 451-460
    • Jenny, N.S.1
  • 103
    • 55749090490 scopus 로고    scopus 로고
    • New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways
    • Ivanenkov Y.A., Balakin K.V., Tkachenko S.E. New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways. Drugs in R&D 2008, 9:397-434.
    • (2008) Drugs in R&D , vol.9 , pp. 397-434
    • Ivanenkov, Y.A.1    Balakin, K.V.2    Tkachenko, S.E.3
  • 105
    • 13544249962 scopus 로고    scopus 로고
    • Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia
    • Martinez-Lostao L., Briones J., Forne I., Martinez-Gallo M., Ferrer B., Sierra J., et al. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma 2005, 46:435-442.
    • (2005) Leukemia and Lymphoma , vol.46 , pp. 435-442
    • Martinez-Lostao, L.1    Briones, J.2    Forne, I.3    Martinez-Gallo, M.4    Ferrer, B.5    Sierra, J.6
  • 106
    • 79953655788 scopus 로고    scopus 로고
    • CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, Demonstrates Clinical Activity and Pharmacodynamic Effects In patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    • 31
    • Furman R.R., Byrd J.C., Brown J.R., Coutre S.E., Benson D.M., Wagner-Johnston N.D., et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, Demonstrates Clinical Activity and Pharmacodynamic Effects In patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood 2010, 116. 31.
    • (2010) Blood , vol.116
    • Furman, R.R.1    Byrd, J.C.2    Brown, J.R.3    Coutre, S.E.4    Benson, D.M.5    Wagner-Johnston, N.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.